{"id":"vts-k","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Dizziness"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting Nav1.6, VTS-K reduces the excitability of neurons, which can help alleviate symptoms of certain neurological disorders. This mechanism of action is thought to be responsible for the therapeutic effects of VTS-K, although the exact mechanisms underlying its clinical benefits are still being studied.","oneSentence":"VTS-K is a small molecule that acts as a selective inhibitor of the sodium-activated potassium channel, Nav1.6.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:16:01.103Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of focal epilepsy"}]},"trialDetails":[{"nctId":"NCT06805838","phase":"NA","title":"Prolonged Manual Ventilation Simulation","status":"ENROLLING_BY_INVITATION","sponsor":"SafeBVM","startDate":"2025-01-25","conditions":"Manual Ventilation","enrollment":102},{"nctId":"NCT05615948","phase":"PHASE4","title":"Oral Aspirin + Ketamine as Adjunct to Oral Antidepressant Therapy for Depression","status":"COMPLETED","sponsor":"Maimonides Medical Center","startDate":"2022-12-06","conditions":"Treatment Resistant Depression, Major Depressive Disorder, Analgesia","enrollment":15},{"nctId":"NCT04702555","phase":"","title":"Analgesic Efficacy of Orally Administered VTS-K for Pain Management","status":"COMPLETED","sponsor":"Antonios Likourezos","startDate":"2021-01-08","conditions":"Pain, Acute","enrollment":25}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Ketamine + Aspirin"],"phase":"marketed","status":"active","brandName":"VTS-K","genericName":"VTS-K","companyName":"Maimonides Medical Center","companyId":"maimonides-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"VTS-K is a small molecule that acts as a selective inhibitor of the sodium-activated potassium channel, Nav1.6. Used for Treatment of focal epilepsy.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}